Source: iQoncept / Shutterstock
SAB Biotherapeutics (NASDAQ:SABS) just reported results for the first quarter of 2024.
- SAB Biotherapeutics reported earnings per share of -54 cents. This was below the analyst estimate for EPS of -46 cents.
- The company reported revenue of $944,575.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/sabs-stock-earnings-sab-biotherapeutics-for-q1-of-2024/.
©2024 InvestorPlace Media, LLC